In addition, by targeted drug sensitivity analysis, we found that the expression of MAP3K14 was negatively correlated with the sensitivity to a variety of targeted drugs, suggesting that MAP3K14 may be a potential therapeutic target for HCC. The gene discussed is MAP3K14; the disease is hepatocellular carcinoma.